Topic Archives: hypertension

Comments

  • Avatar

    On getting older (now 65), started experiencing negative health effects (overweight, hypertension, leaky gut), and so st...

  • JohnM

    $BLPH long (ouch), rumrunner, thanks for your thoughts. When you say "INO pulse could not sustain patients beyond very s...

  • Avatar

    Another company in a very similar situation (starting Phase III trials) is Reservalogix, RVX.TO, RVXCF, with a C$400M ma...

  • SoGiAm

    $MOLN > MEDIA RELEASE http://e1.marco.ch/publish/konsulenten/20_8155/20180615_EHA_Stockholm.pdf Press Release (PDF...

  • SoGiAm

    $BLPH wow > 8K filed.... http://investors.bellerophon.com/phoenix.zhtml?c=253899&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW...

  • Avatar

    Just thinking, if this is a topical gel, does it need to be wiped clean prior to coitus as there may be the unintended s...

  • Avatar

    Sharon et al - My wife works with the young man's mother and this is a better description of what has happened. He...

  • Avatar

    $BLPH “Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients In Phase 3 INOvation-1 Study Evaluating I...

  • Avatar

    I apologize for being remiss in answering in a timely fashion. I'm allegedly retired, which I've come to learn is more ...

  • Avatar

    $BLPH long fp - Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluati...

  • Avatar

    $APTO ow big time So glad you’re back Doc. I suspected you would be in time for NobleCon. After $APTO retreated a ...

  • Avatar

    Good afternoon - This is a plea for some help. My wife and I have a friend whose young son, 15, went to scout camp and...

  • Avatar

    $BLPH nervous long H.C. Wainwright initiates coverage on Bellerophon Therapeutics (NASDAQ: BLPH) with a Buy rating and ...

  • Avatar

    Comment should read " hypertension OR women"....

  • Avatar

    Well written and accurate. This review should be required reading for ALL physicians treating hypertension of women who...

  • Avatar

    $ EIGR NP Eiger BioPharmaceuticals announces that the Phase 2 LIBERTY study in pulmonary arterial hypertension did n...

  • SoGiAm

    $BLPH ow - Title: Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of...

  • SoGiAm

    #NEW http://e.endpointsnews.com/t/ViewEmail/t/4D8DE52AB226DD80/2F80028A944F69C925D77A725F39070E Sanofi’s belated a...

  • Avatar

    $BLPH LONG Bellerophon Therapeutics reports Q3 results (1.35) Co reports Q3 EPS of ($0.22) vs ($0.22) single a...

  • Avatar

    $CWBR $Mitochondria-based therapy $DCA New research report on mitochondria based therapy to treat PAH and cardiov...

  • Avatar

    hi Doc your concerns about fenfluramine $ZGNX were there "However, fenfluramine was withdrawn from global markets in 1...

  • Avatar

    $XLRN np Acceleron gains rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arteria...

  • Avatar

    It's a coin flip, 50% of the time its under the ocular hypertension threshhold therefor not a good indicator for glucoma...

  • Avatar

    Thanks, Cleveland. Your post really helps me place the low MC in perspective. I thought my post was lost and placed anot...

  • Avatar

    $blph long Blph is a strange one to me..as far as trading goes. I don't worry too much about the up's and down's but th...

  • Avatar

    Long $BLPH Doc, one quick question: The Praxair ANDA was for delivery of NO to treat pulmonary hypertension. ...

  • Avatar

    Blph Doc/Helen, PAH (Pulmonary Arterial Hypertension) is Group 1 Pulmonary Hypertension which is essentially high press...

  • Avatar

    Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated wi...

  • Avatar

    $BLPH Doc, I would be very interested in learning whether BLPH has plans, however remote, to trial INOpulse in PAH pa...

  • Avatar

    $ESPR, $PIRS https://www.news-medical.net/news/20170816/Scientists-reveal-engineered-fusion-protein-that-could-recove...

  • Avatar

    $ Meth $Addiction $Stroke "Methamphetamine Use Tied to Heightened Hemorrhagic Stroke Risk" Medscape, August 25, 201...

  • Avatar

    The most common types of cardiovascular disease include hypertension, ischemic heart disease, cerebrovascular disease (s...

  • Avatar

    $BLPH A nice, lucid article published on a professional website, with key information about Bellerophon's innovative ...

  • SoGiAm

    $BLPH long – Join our KOL Webcast on Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) Wednesd...

  • SoGiAm

    $BLPH long - Join our KOL Webcast on Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) Wednesday...

  • Avatar

    $BLPH long 10:52 EDT BLPH theflyonthewall.com: Bellerophon to host a Key Opinion Leader Luncheon Key Opinion Le...

  • DrKSSMDPhD

    $GILD speculated to be eyeing United Therapeutics ($UTH), which markets several pulmonary hypertension drugs, for takeov...

  • Avatar

    $BLPH full position Yes, I saw that. At the end of the announcement, they talk about a KOL meeting on Aug. 9th. K...

  • Avatar

    $BLPH Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associate...

  • Avatar

    $BLPH Marsupi - I am guessing you are looking at the July 31 date on the Gummie Google calendar for data on Ph 2 prog...

  • AC/DC

    $BLPH INOpulse delivery device Pulmonary Hypertension associated with COPD (PH-COPD) Ph2 data is due by the end of this ...

  • Avatar

    To be fair, I should mention that no matter what, voclosporin will always have a better side effect profile than cyclosp...

  • Avatar

    $AUPH long Hi jocn16. Not enough data published to form an opinion on why the P3 trial failed to reach it's prima...

  • DrKSSMDPhD

    I don't personally, but I've considered it many times. In my view, the disease is insulin resistance, and diabetes is it...

  • Avatar

    $ARNA: I think ARENA has two shots that look reasonable.. the PAH (Pulmonary Arterial Hypertension) side first cab off t...

  • Avatar

    Yes $BLPH Corp website confirms they are planning a mid-2017 release of the Ino-Pulse data for Pulmonary Hypertension as...

  • Avatar

    $BLPH They should be releasing Phase 2 results for NO in COPD hopefully within next few weeks. I lifted this from SA...

  • JohnM

    7/24/15 Dr. KSS MD PhD Fundamentally, Kenny, your objection is the correct one. Most of the vitamin D literature is pu...

  • Avatar

    Q4 2017 Catalysts: Achaogan $AKAO (fp) Plazomycin NDA "2H'17" Portola $PTLA (fp) Possible launch of Andexanet 4Q 201...

  • Avatar

    Several July '17 catalysts coming: Windtree $WINT (sp) Phase 2 results due Recro Pharma $REPH (mp) NDA for IV Meloxica...

  • DrKSSMDPhD

    Not any, really. They aim to treat proopiomelanocortin deficiency states which few MD's ever see during a career. Even i...

  • DrKSSMDPhD

    Thanks paul. I am predicting a positive read. I feel the supporting basic science is good and marches in tune to the cli...

  • Avatar

    $No ticker Life expectancy varies from place to place in the US from as much as 86 years to as few as 66. What correl...

  • Avatar

    $BLPH Jabber, I totally forgot about the SPA for the Phase 3. Here is from company's press release March 2017: The ...

  • DrKSSMDPhD

    Agree.....media have whipped anything pertaining to antimicrobials into a frenzy, and few who write get what is clinical...

  • Avatar

    $PTLA, $VBLT, $BLPH, $WINT, $SNDX, $AKAO, $REPH Thanks everyone for your input. I realize my idea is NOT a very good s...

  • Avatar

    $BLPH - LP Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced a poster pr...

  • Avatar

    Frank - As mentioned to earlier, I have a question needing to be answered. I was rereading Dr. KSS' article about $BLPH...

  • Avatar

    Here it is: “Moreover, we expect to communicate the results of our Phase 2 trials for INOpulse therapy to treat sig...

  • Avatar

    $BLPH Doc, From: http://investors.bellerophon.com/phoenix.zhtml?c=253899&p=irol-newsArticle&ID=2220490 “Ou...

  • Avatar

    $BLPH Long: From their Third Quarter 2016 Financial Results report. “Our Phase 2 trials for INOpulse therapy to trea...

  • Avatar

    $BLPH From http://investors.bellerophon.com/phoenix.zhtml?c=253899&p=RssLanding&cat=news&id=2253367 "“Mor...

  • Avatar

    Eyedoc, I'd be interested in your impressions of Aerie Pharmaceuticals ($AERI). They have 2 Phase III trials for gla...

  • Avatar

    $BLPH (long) Just started a position in BLPH at 1.60. Trading extremely well. Phase 2 data (pulmonary hypertension as...

  • DrKSSMDPhD

    Buon giorno and happy Ides of February (I know) to all. Someone posted a question overnight that I saw in the small hour...

  • DrKSSMDPhD

    Oh absolutely, Cyclosporin is a wonder drug and a horrible agent all at the same time. It saves lives not salvageable by...

  • DrKSSMDPhD

    An important new study has appeared in flagship journal Gastroenterology. It confirms strongly a long-held belief among ...

  • Avatar

    Thanks to Doc for bringing up this fascinating topic and for the great discussion following. I am, frankly, flabbergaste...

  • arch1

    Makes me wonder about Tenormin/Atenolol. I do know that street users of ephedrine/amphetamine/meth use bootleg Atenolo...

  • Avatar

    $ITEK no position. The mechanism of action of Trabodenoson in humans as postulaed on the company website is differen...

  • Avatar

    The following current language is from $ITEK's website describing Trabodenoson: "This is a potential new approach to eff...

  • DrKSSMDPhD

    Hi...we've only superficially touched on pulmonary hypertension and agents to treat it. PH is a complex field because so...

  • Avatar

    Happy after Thanksgiving to all. I hope the Gummune has recovered from its calorie induced daze. I took a market holiday...

  • arch1

    $GILD news NP; http://www.gilead.com/news/press-releases/2016/9/gilead-terminates-phase-23-study-of-gs5745-in-patient...

  • Avatar

    #NASH $GILD $GNFTF Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatiti...

  • DrKSSMDPhD

    Hi Frank: I have been tracking Eiger closely from its earliest days, as I know one of the VC's who helped start it. Whil...

  • Avatar

    $AUPH Aurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30th in New York. The C...

  • DrKSSMDPhD

    I often kvetch here about the sorry state of science. And you may think it's carping, that it's affectational bellyachin...

  • SoGiAm

    Author: JohnM Comment: http://www.stockgumshoe.com/2016/08/ten-common-biotech-investing-mistakes/comment-page-12/#comme...

  • JohnM

    $PTN no position Slingshot Insights upcoming call Bremelanotide Phase 3 Data Is Days Away In Female Sexual Dysfunction...

  • DrKSSMDPhD

    Well, this is an interesting find Ben. Sparsentan was being advanced by Retrophin (not to be confused with Recro Pharma)...

  • DrKSSMDPhD

    Hi Zimmy: I'm pretty strongly confident in the abilities of the drugs of both Fibrogen and Akebia to really wring out th...

  • arch1

    Ben $KTOV has said it intends to ask to matket it's hypertension drug. Thjat is a crowded field and apparently they hav...

  • Avatar

    Long $RLYP. I am "re-invested" after the surprising FDA "decision" about ZS9 has been published. The paradigm has shif...

  • Anamorph

    Here is a recent medical journal letter from Dr Bakris responding to and refuting an article that seemed to find some fl...

  • DrKSSMDPhD

    For anyone reading who has tinnitus, I think it's important not to presume it's an innocent process with no cause and no...

  • Avatar

    Dr. KSS, I don't have an opinion I would feel comfortable offering to you but I found the following on $RETA: Reata ...

  • Avatar

    Hi TWA14; I am not a doctor. I have borderline high blood pressure (around 140 + or - 10). but your's sounds dangerously...

  • SoGiAm

    RLYP long and longest Gummune and Twerpz :-) Merci beaucoup - Ben Biggest near-term lift to $RLYP is ZS-9 PDUFA on May...

  • DrKSSMDPhD

    To niizajim: Hi, you were asking the other night about PPI and renal injury. I am really disappointed to hear that your ...

  • LongOnLife

    Thanks for this Dr. KSS. It is pertinent to us older men with low T and the results jive with my experience and gut feel...

  • Avatar

    In my 86th year, I find I am lonesome for all my contemporaries who smoked, since almost without exception they are dead...

  • SoGiAm

    Quantum Genomics Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission ...

  • Avatar

    $CNAT, $GNFTF Doc you wrote in http://www.stockgumshoe.com/2014/12/microblog-dawn-of-the-planet-of-the-tloglodytes/ ...

  • Avatar

    KITOV http://finance.yahoo.com/news/kitov-pharmaceuticals-pivotal-phase-iii-120000858.html Kitov Pharm (KTOV) drug KIT...

  • Avatar

    Akebia (AKBA) Akebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology K...

  • Avatar

    Just ran across the following published today on RLYP: Tomorrow is the FDA's action date for its review of Relypsa's (R...

  • Avatar

    topical H2O2 for Seb K's was of course patentable. I digress. Minoxidil was used for the Rx of severe hypertension for...

  • SoGiAm

    GILD- U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis® with Tadalafil for P...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info